A Phase 2 interventional study of ATH434 in Multiple System Atrophy, sponsored by Alterity Therapeutics. Completed at 1 site in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Alterity Therapeutics · Phase 2, Interventional, and Treatment
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
This study's enrollment of 10 is below the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Browse Multiple System Atrophy studies →Alterity Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ATH434
ATH434 taken by mouth two times per day
Change in brain volume as measured by MRI
Time frame: Change from Baseline to Week 52
Change in iron content in substantia nigra as measured by MRI
Time frame: Change from Baseline to Week 52
Change in Unified MSA Rating Scale (UMSARS) Score
Time frame: Change from Baseline to Week 52
Change in Patient Global Impression of Change (PGI-C)
Time frame: Change from Baseline to Week 52
Change in Clinical Global Impression of Change (CGI-C)
Time frame: Change from Baseline to Week 52
Change in Neurofilament Light Chain Levels
Time frame: Change from Baseline to Week 52
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ATH434
Alterity Therapeutics